ZNRF1

ZNRF1 is a membrane-associated RING-type E3 ubiquitin ligase that functions as a stress- and signal-activated hub coordinating protein degradation, receptor trafficking, and membrane protein homeostasis across neuronal and immune cell contexts. Its catalytic activity is controlled by tyrosine 103 phosphorylation—mediated by EGFR (downstream of NADPH oxidase-generated ROS) or c-Src kinase (downstream of TLR3)—enabling ZNRF1 to ubiquitinate substrates including AKT (K48-linked, proteasomal degradation driving GSK3β-CRMP2–dependent axonal degeneration and axon initial segment positioning), caveolin-1 (K48-linked, amplifying TLR4-driven inflammation), EGFR (endosome-to-lysosome sorting distinct from CBL), and TLR3 (K63-linked, multivesicular body sorting to terminate type I interferon signaling) (PMID:22057101, PMID:26572622, PMID:28593998, PMID:33996800, PMID:37158982). Structurally, its RING domain engages the E2 Ube2N with nanomolar affinity, and an unusual stoichiometry-dependent inhibition mechanism modulates ubiquitin chain assembly; its UBZ domain mediates substrate recognition, as shown for the Na⁺/K⁺-ATPase α1 subunit (PMID:29626159, PMID:22797923). Beyond degradative ubiquitination, ZNRF1 E3 ligase activity supports the Munc18-2–Syntaxin-3 SNARE interaction required for FasL surface trafficking in macrophages and regulates MHC class II surface expression on myeloid cells, linking it to cytotoxic effector function and antigen presentation (PMID:41896526, PMID:41126242).

1. 2009 Medium

   Identification of β-tubulin (Tubb2) as a ZNRF1 interactor established that ZNRF1 associates with cytoskeletal components and that its RING and zinc finger domains are required for morphological effects on neurites, providing the first functional hints beyond its predicted E3 ligase domain structure.

   Evidence Yeast two-hybrid screen and co-immunoprecipitation in neuronal-like cells with domain deletion analysis

   PMID:19737534

   Open questions at the time

   • Single lab, single Y2H/Co-IP without reciprocal validation
   • Whether Tubb2 is a ubiquitination substrate was not tested
   • Morphological readout lacked mechanistic resolution
2. 2011 High

   Demonstration that ZNRF1 ubiquitinates AKT for proteasomal degradation, relieving GSK3β inhibition and driving CRMP2 phosphorylation-dependent microtubule disassembly, established the first complete signaling pathway through which ZNRF1 promotes Wallerian degeneration.

   Evidence Neuronal overexpression/knockdown, ubiquitin-proteasome assays, epistasis with constitutively active GSK3β and CRMP2 phosphomutants, axonal degeneration assays

   PMID:22057101

   Open questions at the time

   • Upstream activation mechanism of ZNRF1 was unknown
   • Whether AKT degradation by ZNRF1 operates outside neurons was untested
3. 2012 High

   Reconstitution of ZNRF1-mediated K63-linked ubiquitination of the Na⁺/K⁺-ATPase α1 subunit via Ubc13/Uev1a, and mapping of its N-myristoylation-dependent membrane association and UBZ-domain-mediated substrate recognition, defined the biochemical architecture of ZNRF1 as a membrane-associated E3 with chain-type specificity.

   Evidence In vitro ubiquitination reconstitution, domain mapping, subcellular fractionation, Co-IP

   PMID:22797923

   Open questions at the time

   • Functional consequence of Na⁺/K⁺-ATPase K63-ubiquitination (degradation vs. trafficking) was not resolved
   • Structural basis of UBZ-substrate recognition unknown
4. 2015 High

   Discovery that oxidative stress activates ZNRF1 through EGFR-dependent phosphorylation at Y103, downstream of NADPH oxidase, answered how ZNRF1 ligase activity is switched on and linked receptor tyrosine kinase signaling to axonal degeneration.

   Evidence Y103 mutagenesis, EGFR and NADPH oxidase pharmacological inhibition, ligase activity and neuronal degeneration assays

   PMID:26572622

   Open questions at the time

   • Whether other kinases phosphorylate Y103 was not explored
   • Whether Y103 phosphorylation regulates all ZNRF1 substrates or only AKT was unknown
5. 2017 High

   Identification of caveolin-1 as a ZNRF1 substrate in macrophages, degraded via K48-linked ubiquitination upon LPS stimulation, expanded ZNRF1 function from neurons to innate immunity, showing it amplifies TLR4-driven pro-inflammatory cytokine production by modulating AKT-GSK3β signaling.

   Evidence Reciprocal Co-IP, ubiquitination assays, hematopoietic ZNRF1 KO mice, endotoxic shock model with cytokine measurements

   PMID:28593998

   Open questions at the time

   • Whether ZNRF1 is transcriptionally induced by LPS or post-translationally activated was not fully resolved
   • Direct ubiquitination site on CAV1 not mapped
6. 2018 High

   Crystal structure of the ZNRF1 RING domain bound to Ube2N at ~50 nM affinity, compared with ~1 µM for Ube2D2, revealed the structural basis for E2 selectivity and an unusual stoichiometry-dependent inhibition mechanism whereby excess ZNRF1 suppresses ubiquitin chain assembly.

   Evidence X-ray crystallography, isothermal titration calorimetry, in vitro ubiquitination with mutagenesis

   PMID:29626159

   Open questions at the time

   • Whether stoichiometric inhibition operates in vivo was not demonstrated
   • Full-length ZNRF1 structure including UBZ domain remains unsolved
7. 2021 High

   Showing that ZNRF1 ubiquitinates EGFR at sites distinct from CBL to promote endosome-to-lysosome sorting established ZNRF1 as a non-redundant regulator of receptor tyrosine kinase trafficking, with loss of ZNRF1 prolonging downstream signaling and increasing HSV-1 susceptibility.

   Evidence ZNRF1 KO cells, ubiquitin site mapping on EGFR, endosomal/lysosomal trafficking and degradation assays

   PMID:33996800

   Open questions at the time

   • Whether ZNRF1 targets other receptor tyrosine kinases beyond EGFR was not tested
   • Mechanism of ZNRF1 recruitment to endosomes not defined
8. 2023 High

   Demonstration that c-Src phosphorylates ZNRF1 Y103 downstream of TLR3, enabling K63-linked ubiquitination of TLR3 at K813 for MVB/lysosomal sorting, unified the Y103 activation mechanism across RTK and innate immune signaling and identified a negative feedback loop terminating type I interferon responses.

   Evidence ZNRF1-deficient mice and cells, Y103 and K813 site-directed mutagenesis, ubiquitination and endolysosomal trafficking assays, EMCV and SARS-CoV-2 infection models

   PMID:37158982

   Open questions at the time

   • Whether ZNRF1 regulates other TLRs via similar K63-ubiquitination was not tested
   • In vivo kinetics of TLR3 turnover in ZNRF1 KO during infection not fully characterized
9. 2023 Medium

   LZTFL1-dependent recruitment of ZNRF1 to AKT for proteasomal degradation in kidney tumor cells established that the ZNRF1-AKT axis operates in cancer contexts and is regulated by upstream tumor suppressors.

   Evidence Gain- and loss-of-function in kidney tumor cell lines, patient-derived xenograft model

   PMID:36966254

   Open questions at the time

   • How LZTFL1 recruits or activates ZNRF1 mechanistically is unclear
   • Whether Y103 phosphorylation is involved in tumor cell context not addressed
10. 2024 Medium

    Discovery that the Drosophila ZNRF1/2 ortholog Detour ubiquitinates HOPS complex subunits (VPS18, VPS16A, VPS41) to regulate autophagosome-lysosome fusion, with mammalian ZNRF1/2 loss increasing basal autophagy, extended the substrate repertoire to vesicle tethering machinery and autophagy regulation.

    Evidence Drosophila genetic screen, mass spectrometry interactome, ubiquitination assay, autophagy flux assays in mammalian cells

    PMID:38360932

    Open questions at the time

    • Drosophila ortholog may have divergent specificity from mammalian ZNRF1
    • Whether ZNRF1 specifically (vs. ZNRF2) ubiquitinates mammalian HOPS subunits not resolved
    • Ubiquitin chain type on HOPS subunits not determined
11. 2025 Medium

    ZNRF1 KO mice revealed that ZNRF1-dependent AKT degradation positions the axon initial segment and controls Nav1.2 surface expression, linking the E3 ligase to neuronal excitability and fear memory, extending the AKT substrate axis to a systems-level behavioral output.

    Evidence ZNRF1 KO mice, AIS morphometry, Nav1.2 surface biotinylation, fear conditioning behavioral assay

    PMID:40331626

    Open questions at the time

    • Whether Nav1.2 is a direct ZNRF1 substrate or an indirect consequence of AKT-GSK3β signaling not resolved
    • Single lab finding
12. 2025 Medium

    Myeloid-specific ZNRF1 KO showed elevated surface MHC class II on macrophages, enhanced T cell priming, and exacerbated EAE, establishing ZNRF1 as a negative regulator of antigen presentation and autoimmune neuroinflammation.

    Evidence Myeloid-specific ZNRF1 KO mice, flow cytometry, EAE model, T cell proliferation assays

    PMID:41126242

    Open questions at the time

    • Whether ZNRF1 directly ubiquitinates MHC-II or acts indirectly (e.g., via CAV1 or trafficking) not determined
    • Single lab, single disease model
13. 2026 High

    Reconstitution experiments with catalytically dead ZNRF1 (C184A) demonstrated that ZNRF1 E3 ligase activity supports the Munc18-2–Syntaxin-3 SNARE complex required for FasL surface trafficking, revealing a non-degradative role in vesicle docking/fusion at the plasma membrane.

    Evidence Myeloid-specific ZNRF1 KO, C184A catalytic mutant reconstitution, Stxbp2-Stx3 Co-IP, confocal imaging, surface FasL flow cytometry, FasL-dependent killing assays

    PMID:41896526

    Open questions at the time

    • Direct ubiquitination substrate enabling Munc18-2–Stx3 interaction not identified
    • Whether this SNARE-regulatory function extends to other secretory cargoes unknown

• Key unresolved questions include: the identity of the direct ubiquitination target through which ZNRF1 controls the Munc18-2–Stx3 SNARE complex; whether ZNRF1 directly ubiquitinates MHC-II; the full-length ZNRF1 structure including UBZ domain; and how stoichiometry-dependent E2 inhibition operates in physiological settings.
• No full-length structural model
• Direct MHC-II ubiquitination by ZNRF1 not tested
• SNARE-regulatory substrate unidentified
• In vivo relevance of stoichiometric E2 inhibition not demonstrated